Process Modernisation for Licensed Biopharmaceuticals Nigel Allison at the UK Health Protection Agency considers process
modernisation in biopharmaceutical manufacturing, emphasising
that a product’s position in the market can be maintained through
moderate adaptations, without the need for extensive new
clinical trials. Nigel Allison (September 2011)
Keywords: Nigel Allison at the UK Health Protection Agency considers process
modernisation in biopharmaceutical manufacturing, emphasising
that a product’s position in the market can be maintained through
moderate adaptations, without the need for extensive new
clinical trials.
|
